



Art Unit: 1644

Box / Seq  
# 9/10  
RECEIVED 1/9/01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Sone et al.

Art Unit : 1644

Serial No. : 09/308,027

Examiner : R. Schwadron

Filed : August 16, 1999

Title : PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT

DEC 14 2000

Commissioner for Patents

Washington, D.C. 20231

TECH CENTER 1800/2900

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

RECEIVED

DEC 18 2000

In response to the communication dated November 7, 2000 (copy enclosed), Applicant submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicant submits a Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.

Respectfully submitted,

Date:

Dec. 7, 2000

Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20177503.doc

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

DECEMBER 7, 2000

Signature

Kathleen Philpot

Typed or Printed Name of Person Signing Certificate

KATHLEEN PHILPOT



Application No.: 09308027

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



PATENT

ATTORNEY DOCKET NO. 06501/031001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Sone et al.

Art Unit: 1644

Serial No.: US 09/308,027

Examiner: R.Schwadron

Filed : May 12, 1999

Title : PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT

Box Sequence

Commissioner for Patents

Washington, DC 20231

RECEIVED

DEC 14 2000

STATEMENT UNDER 37 CFR §1.821(f)

TECH CENTER 1600/2900

I, Maureen Ruttle, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

RECEIVED

DEC 18 2000

Date: December 1, 2000Maureen Ruttle  
Maureen Ruttle

TECH CENTER 1600/2900

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804

Telephone: 617/542-5070

Facsimile: 617/542-8906

Date of Deposit

December 7, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kathleen Philpot  
KATHLEEN PHILPOT